Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V1WQ
|
|||
| Former ID |
DNCL002926
|
|||
| Drug Name |
TAK-875
|
|||
| Synonyms |
TAK-875; Fasiglifam; 1000413-72-8; TAK875; TAK 875; UNII-GLP1W4JXAH; GLP1W4JXAH; (S)-2-(6-((2',6'-Dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid; CHEMBL1829174; [(3s)-6-({2',6'-Dimethyl-4'-[3-(Methylsulfonyl)propoxy]biphenyl-3-Yl}methoxy)-2,3-Dihydro-1-Benzofuran-3-Yl]acetic Acid; 3-Benzofuranacetic acid, 6-[[2',6'-diMethyl-4'-[3-(Methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]Methoxy]-2,3-dihydro-, (3S)-; J-501277
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [1], [2] | |
| Company |
Takeda Pharmaceuticals U.S.A.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H32O7S
|
|||
| Canonical SMILES |
CC1=CC(=CC(=C1C2=CC=CC(=C2)COC3=CC4=C(C=C3)C(CO4)CC(=O)O)C)OCCCS(=O)(=O)C
|
|||
| InChI |
1S/C29H32O7S/c1-19-12-25(34-10-5-11-37(3,32)33)13-20(2)29(19)22-7-4-6-21(14-22)17-35-24-8-9-26-23(15-28(30)31)18-36-27(26)16-24/h4,6-9,12-14,16,23H,5,10-11,15,17-18H2,1-3H3,(H,30,31)/t23-/m1/s1
|
|||
| InChIKey |
BZCALJIHZVNMGJ-HSZRJFAPSA-N
|
|||
| CAS Number |
CAS 1000413-72-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
50088191, 57154181, 134464228, 135268194, 136349531, 136367662, 140817135, 143499812, 152233038, 152258229, 160647065, 160865873, 162011413, 162202766, 164044689, 170501170, 172232430, 172919610, 174006778, 174525708, 174526154, 178103098, 185967135, 191112353, 196409677, 198984389, 203355926, 223375341, 224346112, 226560798, 242587051, 245772988, 249735423, 252110185, 252151428, 252216368, 252450486, 252810271
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Free fatty acid receptor 1 (GPR40) | Target Info | Modulator | [3] |
| KEGG Pathway | Insulin secretion | |||
| Reactome | G alpha (q) signalling events | |||
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Incretin Synthesis, Secretion, and Inactivation | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6484). | |||
| REF 2 | ClinicalTrials.gov (NCT01609582) Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease. U.S. National Institutes of Health. | |||
| REF 3 | Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.